Serial No.: 10/620,404

Applicant: James M. Ntambi

Date of Office Action: 18 June 2010 Date of Response: December 17, 2010

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the above identified application.

Listing of Claims:

- 1.-5. (Canceled)
- (Withdrawn) A method of increasing insulin sensitivity in a human or non-human subject, the method comprising the steps of:
- administering an agent for reducing stearoyl-CoA desaturase 1 (SCD1) activity in the human or non-human subject to increase insulin sensitivity; and
- measuring insulin sensitivity and observing an increase in insulin sensitivity following a reduction in SCD1 activity, wherein the agent is a polyunsaturated fatty acid is selected from the group consisting of dodecahexaenoic acid and arachidonic acid.
- (Previously presented) A method of increasing insulin sensitivity in a human or non-human subject, the method comprising the steps of:
- administering an agent for reducing stearoyl-CoA desaturase 1 (SCD1) activity in the human or non-human subject to increase insulin sensitivity; and
- measuring insulin sensitivity and observing an increase in insulin sensitivity following a reduction in SCD1 activity, wherein the agent is an antisense oligonucleotide for SCD1.

Serial No.: 10/620,404

Applicant: James M. Ntambi Date of Office Action: 18 June 2010

Date of Response: December 17, 2010

8. (Withdrawn) A method of increasing insulin sensitivity in a human or non-human subject, the method comprising the steps of:

administering an agent for reducing stearoyl-CoA desaturase 1 (SCD1) activity in the human or non-human subject to increase insulin sensitivity; and

measuring insulin sensitivity and observing an increase in insulin sensitivity following a reduction in SCD1 activity, wherein the agent reduces SCD1 activity by inhibiting enzymatic activity of SCD1.

- 9. (Withdrawn) The method of claim 8, wherein the agent is an SCD1 inhibitor.
- (Withdrawn) The method of claim 9, wherein the agent that inhibits enzymatic activity of SCD1 is an anti-SCD1 antibody.
- 11. (Withdrawn) The method of claim 8, wherein the agent that inhibits SCD1 enzymatic activity inhibits a protein selected from the group consisting of a cytochrome b₅ protein, a NADH-cytochrome b₅ reductase protein, and a terminal cyanide-sensitive desaturase protein.

12.-13. (Canceled)